SEC Filing Summary: Spherix Incorporated (Form 10-Q)
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2007. Spherix Incorporated (Registrant) underwent a significant strategic shift during the period. On August 15, 2007, the Company sold its InfoSpherix subsidiary, which previously comprised the majority of its operations. Consequently, InfoSpherix results are reported as discontinued operations. The Company is now focusing exclusively on the BioSpherix division, specifically the commercialization of Naturlose (tagatose) as a treatment for Type 2 diabetes, and a newly launched health sciences consulting business.
Key Financial Metrics
Revenue and Profitability (Nine Months Ended Sept 30, 2007):
- Total Revenue: $15,433,000 (Continuing: $62,519; Discontinued: $15,371,000).
- Net Income: $1,257,775 (Driven primarily by the gain on sale of InfoSpherix).
- Loss from Continuing Operations: $(7,238,502).
- Income from Discontinued Operations: $8,320,709 (Includes $8,567,000 gain on sale).
- EPS (Basic/Diluted): $0.09 (Net); $(0.50) from continuing operations; $0.59 from discontinued operations.
Liquidity and Balance Sheet (As of Sept 30, 2007):
- Cash and Cash Equivalents: $18,689,654 (Increased from $9,863,771 at year-end 2006).
- Total Assets: $19,535,625.
- Total Liabilities: $2,904,126.
- Working Capital: Approximately $17.0 million.
- Debt: No fixed-rate or variable-rate indebtedness as of September 30, 2007. The line of credit associated with InfoSpherix was terminated.
Cash Flow (Nine Months Ended Sept 30, 2007):
- Operating Activities: Net cash used of $(5,475,522) (Continuing operations used $5.4M; Discontinued used $94k).
- Investing Activities: Net cash provided of $13,669,683 (Primarily $15M proceeds from InfoSpherix sale).
- Financing Activities: Net cash provided of $631,722 (Includes $757,500 from stock issuance).
Material Changes vs. Prior Period
- Revenue Structure: Continuing operations revenue is negligible ($62,519 for nine months) compared to the prior year, as the Company has divested its primary revenue-generating segment (InfoSpherix). The prior year's revenue was dominated by InfoSpherix.
- Operating Expenses: Continuing operating expenses increased significantly to $7,301,021 (nine months 2007) from $2,433,961 (nine months 2006). This is largely due to a surge in Research and Development (R&D) expenses ($4,477,278 vs. $722,654) driven by the Phase 3 clinical trial for Naturlose.
- Profitability: While the Company reported a net loss in the prior year, the current period shows a net income due to the one-time gain from the sale of InfoSpherix. Without discontinued operations, the Company incurred a substantial loss from continuing operations.
- Liquidity: Cash reserves nearly doubled due to the $15 million cash proceeds received at the closing of the InfoSpherix sale.
Guidance, Outlook, and Risks
Outlook and Strategy:
- Phase 3 Clinical Trial: The primary focus is the Phase 3 trial for Naturlose to treat Type 2 diabetes, which began in April 2007. Testing is scheduled to finish in mid-2009. FDA approval is not expected before mid-to-late 2010 at the earliest.
- Capital Allocation: The Company expects to expend approximately $5 million over the next year on R&D and the clinical trial, funded by the proceeds from the InfoSpherix sale.
- Consulting Business: A new health sciences consulting division was launched in July 2007 to provide technical and regulatory services, generating minimal revenue to date.
- Management Changes: Richard C. Levin resigned as CEO/CFO upon the sale of InfoSpherix. Claire L. Kruger was elected as the new CEO and COO.
Risks and Contingencies:
- Clinical Trial Failure: The Company's future viability depends on the success of the Naturlose Phase 3 trial. A smaller anti-plaque trial conducted earlier in the year showed no statistical significance and was discontinued.
- Regulatory Approval: There is no assurance that the FDA will approve Naturlose, even if the trial is successful.
- Capital Needs: While current cash reserves are sufficient for the next year, the Company may need to seek additional financing (e.g., stock sales) if the trial extends or costs exceed estimates.
- Tax Liabilities: The sale of InfoSpherix resulted in a state income tax expense of approximately $762,541, as the subsidiary had no net operating loss carryforwards to offset the gain.
Investor Verification Checklist
- Verify the status and enrollment numbers of the Naturlose Phase 3 clinical trial for Type 2 diabetes.
- Confirm the timeline and budget for the remaining $5 million R&D expenditure over the next 12 months.
- Review the terms of the InfoSpherix sale escrow ($2 million payable after 15 months) and potential indemnification claims.
- Assess the revenue trajectory of the new health sciences consulting business to determine if it can offset operating costs.
- Monitor the Company's cash burn rate relative to the $18.7 million cash balance to ensure sufficiency through the trial completion in 2009.